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Abstract 
The role of the CAMKK pathway in object recognition memory was investigated. Rats’ 
performance in a preferential object recognition test was examined after local infusion into the 
perirhinal cortex of the CAMKK inhibitor STO-609. STO-609 infused either before or 
immediately after acquisition impaired memory tested after a 24h but not a 20min delay. 
Memory was not impaired when STO-609 was infused 20min after acquisition. The 
expression of two downstream reaction products of CAMKK was measured by 
immunohistochemical staining for phospho-CAMKIThr177 and phospho-CAMKIVThr196 at 10, 40, 
70 and 100 min following the viewing of novel and familiar images of objects. Processing 
familiar images resulted in more pCAMKI stained neurons in the perirhinal cortex than 
processing novel images at the 10min and 40min delays. Perirhinal neuronal counts for 
pCAMKIV were lower than for pCAMKI and no differential effects of processing novel and 
familiar images were found for pCAMKIV. Prior infusion of STO-609 caused a reduction in 
pCAMKI stained neurons in response to viewing either novel or familiar images, consistent 
with its role as an inhibitor of CAMKK. The results establish that the CAMKK pathway within 
the perirhinal cortex is important for the consolidation of object recognition memory. The 
immunohistochemical imaging for pCAMKI indicated that CAMKI might be involved in 
reconsolidation mechanisms for familiar stimuli in addition to consolidation mechanisms for 
novel stimuli. The activation of pCAMKI after acquisition is earlier than previously reported for 
pCAMKII. In contrast to CAMKI and CAMKII, CAMKIV appears to be unimportant for 
perirhinal recognition memory processes. 
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Introduction 
The calcium-calmodulin dependent protein kinase enzymes (CAMKs) form intracellular 
signalling pathways in neurons and have been implicated in memory processes in the brain 
(Wayman et al., 2008). The CAMK family includes CAMKI, CAMKII, CAMKIV and CAMK-
kinase (CAMKK), all of which are activated by Ca2+-calmodulin. CAMKII is a multisubunit 
enzyme with an intracellular signalling pathway that is distinct from those of CAMKK, CAMKI 
and CAMKIV. CAMKK is known to activate both CAMKI and CAMKIV by phosphorylation of 
the Threonine177 and Threonine196 residues respectively (Soderling, 1999). CAMKI is 
described as residing in the cytoplasm of cells (Picciotto et al., 1995) whereas CAMKIV has 
been located in the nucleus (Jensen et al., 1991). There is increasing evidence that the 
CAMKK pathway plays an important role in memory. CAMKKα mutant mice show impaired 
fear memory (Blaeser et al., 2006; Mizuno et al., 2006) and CAMKKβ mutant mice exhibit 
impaired spatial memory formation (Peters et al., 2003). Additionally, pharmacological 
inhibition of CAMKK has been shown to impair induction of long-term potentiation (LTP) in the 
hippocampus (Schmitt et al., 2005). However, the role of CAMKK in recognition memory has 
not been previously investigated. 
Recognition memory is impaired by lesions of the perirhinal cortex (Zola-Morgan et al., 
1989; Gaffan and Murray, 1992; Meunier et al., 1993; Mumby and Pinel, 1994; Ennaceur et 
al., 1996; Meunier et al., 1996; Brown and Aggleton, 2001; Brown et al., in press). Further, 
some neurons within the perirhinal region respond more strongly to novel than familiar visual 
stimuli (Brown et al., 1987; Zhu et al., 1995a; Desimone, 1996; Xiang and Brown, 1998). 
Immunohistochemical imaging indicates that this difference in response is paralleled by a 
higher Fos expression produced within perirhinal cortex by viewing novel rather than familiar 
images (Zhu et al., 1995; Zhu et al., 1996). 
Here we establish a role and time course for CAMKK and CAMKI activity in object 
recognition memory within the rat perirhinal region by using localised infusion of a CAMKK 
inhibitor, STO-609. STO-609 inhibits both CAMKKα and CAMKKβ (Tokumitsu et al., 2002). 
Additionally, we establish the time course of the differential immunohistochemical staining for 
one of the reaction products of CAMKK, pCAMKIThre177 (an activated form of CAMKI), 
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produced by viewing novel or familiar pictures, and that this differential activation is blocked 
by STO-609. 
Materials and Methods 
Animals 
Dark Agouti male rats (Bantin and Kingman, Hull, UK) underwent behavioural testing 
in the preferential object recognition task or underwent a paired viewing procedure (see 
below). Nineteen (230-300g) were used in preferential object recognition experiments, 2 in 
the western blotting experiment (200-220g) and 40 (200-250g) in the paired viewing 
experiments. The animals were housed under a 12 h light/dark cycle (light phase, 18.00 to 
6.00). Experiments were conducted during the dark phase of the cycle. All animal procedures 
were performed in accordance with the United Kingdom Animals Scientific Procedures Act 
(1986) and were approved by the University of Bristol Ethical Committee. 
Experiment 1 –Infusion of the CAMKK antagonist STO-609 during the preferential 
object recognition test 
Surgery 
Prior to testing in the preferential object recognition test rats underwent surgical 
procedures to implant guide cannulae into the perirhinal cortex. Rats were anaesthetised with 
isoflurane (Merial, Harlow, UK) and placed in a stereotaxic frame with the incisor bar set so as 
to achieve a flat skull. Craniotomies were made 5.6mm posterior and 4.5mm lateral to bregma, 
and 10mm length 26 gauge stainless steel guide cannulae (Plastics One, VA) were inserted 
6.7mm below the surface of the skull in the coronal plane at an angle of 20 degrees to the 
vertical. The cannulae were attached to the surface of the skull by constructing an implant 
made from bone cement (DePuy, UK) and attached to the skull with stainless-steel screws 
(Plastics One). After surgery, rats were allowed a 2 week recovery period during which they 
were housed singly. Post-recovery, cannulated rats were housed in pairs in large cages. 
Obdurators (Plastics One) were used to keep the cannulae patent between infusions. 
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Pretraining 
Rats were habituated to an arena (length: 100cm, depth: 100cm, arena height: 40cm) 
surrounded by curtains, (height: 40-160cm) in 5 min periods each day for 4 days. 
Behavioural testing and infusions 
During the acquisition trial each rat was initially exposed to two identical copies of an 
object (Object A) until it had explored the objects for more than 40s or for a maximum of 4 min. 
Objects were constructed from Duplo™(Lego UK, Slough, UK) (length: ~16cm, depth: ~16cm, 
height: ~12cm). After a delay period, of 24h, each rat was exposed to another copy of Object 
A and a novel object (Object B) in a choice trial lasting 3 min. Rats received bilateral infusions 
of CAMKK inhibitors into their perirhinal cortex using 33 gauge infusion cannulae (Plastics 
One, VA) inserted into the implanted guide cannula and attached to a 25µl Hamilton syringe 
by polyethylene tubing. An infusion pump (Harvard Bioscience, Holliston, MA) was used to 
inject a volume of 1µl to each hemisphere during a 2min period. Infusion cannulae were kept 
in place for a further 5min following the infusion. Drug infusions were made at different time-
points with respect to the acquisition phase. The CAMKK inhibitor STO-609 (Tocris, Bristol, 
UK) was infused into both sides of the perirhinal cortex at a dose of 1ng/side, dissolved in 
0.03% DMSO in 0.9% saline For each time point, the experiment was run in two parts in a 
cross-over design. In the first part, rats were randomly assigned an infusion of drug or vehicle 
(0.03% DMSO in 0.9% saline) and an object recognition experiment was performed. In the 
second part each rat was given the opposite infusate and another object recognition 
experiment was performed using new objects. There was a minimum separation of 48h 
between the two parts of the experiment. 
Data analysis 
Time spent exploring each object was scored blind as to treatment by the 
experimenter using a computer program. Exploratory behaviour was defined as the rat 
directing its nose toward the object at a distance of <2 cm; other behaviour, such as looking 
around while sitting on the object, was not considered exploration. A discrimination ratio (DR) 
was used to measure memory performance and was calculated by dividing the difference in 
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time exploring the novel and the familiar object by the time taken exploring both objects. Rats 
that failed to complete a minimum of 10s exploration in the acquisition trial or 5s exploration in 
the choice trial were excluded from the analysis. Over the course of several experiments, 
occasionally rats had to be excluded from the analysis due to cannula failures. The following 
is a summary of the rats included in the statistical analysis of the inhibitor experiments. There 
were 2 groups of rats used in these experiments, each group consisted of 12 individuals. In 
the first experiment (group 1; n=9 rats) a 20min delay between the acquisition and choice 
trials was used and infusate was injected 15min before the acquisition trial. In the subsequent 
experiments there was a 24h delay between acquisition and choice trials and the time of 
infusion was varied from 15min before the acquisition trial (group 2; n=8 rats), immediately 
[<2min] after (group 1 ; n=9) or 20min after the acquisition trial (group 2; n=10). There was no 
evidence from the behaviour following control infusions that spontaneous exploration or 
familiarity discrimination changed across the course of the experiments. DR values were 
analysed using repeated measures ANOVA with factors treatment (drug/vehicle) and infusion 
time. The significance level was determined as p=0.05, 2-tailed. 
Verification of cannulae positions 
Rats were anaesthetised with Euthatal (Rhône Mérieux, Toulouse, France) and 
transcardially perfused with 0.1M phosphate buffer containing formal saline, pH7.4. Coronal 
sections (40μm) were cut on a freezing microtome and the sections were stained with cresyl 
violet. Cannula locations were compared to a stereotaxic atlas (Paxinos and Watson, 1998) 
and histological examination confirmed that the tips of the cannulae were within the perirhinal 
cortex (Shi and Cassell, 1999); Fig. 1A. Data from other laboratories (Martin, 1991; Izquierdo 
et al., 2000; Attwell et al., 2001) and our unpublished data indicate that the infused tissue 
extended to an approximately 0.5-1mm radius from the cannula tip. This volume includes the 
majority of perirhinal cortex (Shi and Cassell, 1999) but only minor parts of neighbouring 
entorhinal cortex or area Te2. 
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Experiment 2 - Western blotting of pCAMKI and pCAMKIV antibodies onto perirhinal 
cortex and Te2 cortical lysate. 
The rats were placed in a novel cage for 20min and then anaesthetised with 
isoflurane and their brains removed. Perirhinal cortex and area Te2 were dissected and 
immediately placed into phosphate buffer. The tissue samples were then transferred into lysis 
buffer (50mM Tris HCl (pH 7.4), 1% triton X-100, 0.1% SDS, 1mM EDTA pH 8.0, protease 
inhibitors (Roche, Herfordshire, UK), phosphatase inhibitors, (Roche)). The brain tissue was 
then homegenised with a sonicator (around 10 strokes). Lysates were left on ice for 1h for the 
proteins to solubilise and were then spun at 13000rpm for 15min at 4°C. The supernatant was 
collected and a Bradford protein (Biorad) assay was performed to determine the protein 
concentration. Protein samples (50 µg) were next subjected to electrophoresis in a 10% 
acrylamide gel and electrophoretically transferred to a PVDF membrane (Millipore, Watford, 
Uk). Membranes were incubated overnight at 4°C with primary antibody to pCAMKI or 
pCAMKIV (1:200, Santa Cruz, CA: catalogue #s sc-28438-R and sc-28443-R). After 
incubation with horseradish peroxidase-conjugated anti-rabbit secondary antibody at a 
dilution of 1:10000 (Sigma) for 1h, immunolabeled proteins were visualized by 
autoradiography using chemiluminescence ECL (Roche). 
Experiment 3 - Presentation of novel and familiar images followed by 
immunohistochemical staining for pCAMKIThre177 and pCAMKIVThre196 
Apparatus 
Novel and familiar images were presented simultaneously to individual rats under 
carefully controlled conditions (Zhu et al., 1996; Warburton et al., 2005). Each rat was trained 
in a paired viewing chamber (30 x 30 x 35 cm); the top of the chamber was open, the side 
and rear panels were blackened and the front panel was made from clear perspex. In the 
middle of the front panel there was a 3cm observation hole located 6cm above the floor. 
Barriers (12cm long x 9 cm high) were placed 4.5cm on either side of the observation hole to 
ensure the rat’s body was aligned perpendicular with respect to the two monitor screens 
(model 4Vlr; AOC Spectrum, Los Angeles, CA). The monitors were placed 30 cm from the 
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observing hole and a black barrier between the monitors and observation hole ensured that 
the rat’s right eye could not see the left monitor and vice versa. When a rat’s head was in the 
observing hole it interrupted an infra-red beam and its tongue could just reach a metal lick 
tube. A trial began once the rat’s head had continuously interrupted the infra-red beam for a 
randomly variable interval of 3-4s. Each monitor then displayed an image (15 x 12 cm) for 
4.5s. A drop of blackcurrant juice was delivered by the lick tube 0.5s before the end of the 
image display. Stimulus display and juice delivery were computer (Viglen, Pentium II, St 
Albans, UK) controlled. A camera system was used to monitor and record each rat’s 
behaviour during experimental sessions to confirm that the head was positioned as expected 
during stimulus display. The positioning was satisfactory for all rats whose data are reported. 
Training 
Rats were allowed ad libitum access to water for 2h each day. Rats were housed in 
groups of three per cage for the duration of the experiment. Initially rats were trained in the 
paired viewing apparatus for 2 days. During these 2 days rats learned to go to the observation 
hole for juice reward and there was no presentation of images. The next phase lasted for 6 
days and during this time rats saw a series of novel and familiar images. In each morning 
session 30 images, (FAM set) were presented simultaneously to each eye. The images were 
presented in a pseudo-random order to ensure that different images were simultaneously 
shown to each eye. After a delay of 3h the rats were placed back in the apparatus for the 
afternoon session, in which each eye was shown 15 images from the FAM set and 15 novel 
images. During each trial one eye was shown a novel image and the other eye was shown a 
FAM image. Each afternoon a different set of novel images was shown along with the FAM 
image set. Thus prior to the last afternoon each eye had seen the same number of novel and 
familiar images. On the afternoon of the last day 30 novel images (NOV) were shown to one 
eye and the 30 FAM images were shown to the other eye. The effective memory delay was at 
least 3h (the delay between seeing the familiar stimuli during the morning and afternoon 
sessions of the last day). The FAM set for half the animals was the NOV set for the other half 
of the animals; this counterbalanced the image sets across animals. Further, exposure to 
NOV or FAM images to the left or right eye was also counterbalanced. 
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Immunohistochemical staining for pCAMKI 
Rats were transcardially perfused with 0.1M phosphate buffer (PB) containing 50mM 
sodium fluoride (NaF) followed by 4% paraformaldehyde in PB-NaF, pH7.4. The perfusions 
took place at different time points after the final images had been shown; 10 min (n=6), 40 
min (n=6), 70 min (n=7) and 100 min (n=6). The brains were then removed and placed in 4% 
paraformaldehyde in PB-NaF for 24 h, followed by 48 h in 30% sucrose in PB. Coronal 
sections were cut on a freezing microtome at a thickness of 40μm and floating sections were 
processed for immunohistochemistry using the avidin-biotin (ABC; Vector Laboratories) 
method. Sections were washed in Triton Tris buffered saline with 0.2% Triton X-100, 0.08M 
Tris Buffer and 0.9% NaCL (TTBS); they were then blocked with TTBS containing 1 % bovine 
serum albumin (BSA), 5% normal goat serum (NGS). Sections were then incubated in a 
polyclonal rabbit primary antibody to pCAMKI or pCAMKIV (1:200, Santa Cruz, CA: catalogue 
#s sc-28438-R and sc-28443-R) in TTBS containing 0.25% BSA and 5% NGS for 48 hours. 
The secondary antibody used was polyclonal goat anti-rabbit (1:500, Vector Laboratories, 
Peterborough, UK) and 3,3’-diaminobenzine was used for visualisation. 
Double-labelling of pCAMKI and pCAMKIV 
To determine whether pCAMKI and pCAMKIV were co-localised, some sections from 
a rat perfused 10min after viewing novel and familiar images (Experiment 3), were also 
double labelled for pCAMKI and pCAMKIV. This required first single labelling pCAMKI stained 
neurons with the same protocol as detailed above except that the primary antibody was 
applied at a dilution of 1:100 and incubation was for 24h; visualisation was with DAB. After 
blocking with excess avidin and biotin, sections were then labelled with the pCAMKIV 
antibody at 1:100 dilution for 24h and visualised with the purple coloured stain Vector VIP 
(Vector laboratories). 
Data analysis 
All processing and counting were performed blind as to treatment. The pCAMKI-
labelled cells were counted using an automated image analysis system using in-house 
software (CellCountMainv.3.1, J. Leendertz) that counted oval or irregular objects within a 
given size range 10-22μm and that were above a contrast threshold determined against a 
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smoothed surrounding background level. The threshold was preset in preliminary experiments 
so that clearly stained neurons were counted. Sections were viewed using a Leica 
microscope (DM5000B, Leica, Germany) and images (768 x 512 pixels) were shown on a 
screen and were captured at an effective magnification of x240 with 256 grey level resolution. 
Automated counting of neurons was performed in counting frames on both the left and right 
hemispheres for rectangular areas (0.94 x 0.62mm) that included all cortical cell layers from 
two sections from each brain. The counting frames were positioned over perirhinal cortex, 
visual association cortex (here termed Te2), lateral entorhinal cortex, auditory cortex and 
primary visual cortex (Fig. 1C, D). Counts of pCAMKIstained neuronal soma were compared 
between the hemisphere primarily processing novel and that primarily processing familiar 
information. 
Counts of pCAMKIV-stained neurons were made with a different particle counting 
program that was able to count ring-shaped and filled neuronal outlines (Leica Qwin image 
analysis program, Leica, Germany). Particles composed of defined number of pixels were 
counted provided they were of resticted length, this ensured that soma with and without apical 
dendrites were counted but isolated apical dendrite profiles were not. Counting frames were 
the same as those used for the pCAMKI counts. Test images of pCAMKI-stained neurons 
were counted with both types of image counting program and the programs produced 
equivalent counts. 
Stereological corrections were not made because only relative measures were 
sought. To reduce variance across rats and different immunohistochemical batches of 
processed material, counts were normalised: for each rat the mean count for each region in a 
particular hemisphere was divided by the mean count for both hemispheres for that region. 
These data were analysed using a repeated-measures ANOVA with factors stimulus 
repetition (NOV/FAM), area and time (10, 40, 70 or 100 min). The significance level was 
determined as p=0.05, 2-tailed. 
In the CA1 region of the hippocampus cell counts of pCAMKIV could not be made 
due to an unclear separation between neighbouring stained neurons. To obtain a measure of 
staining intensity within this region the strength of staining across the entire counting frame 
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was averaged. These measurements were performed on the same sized counting frames as 
used in the cell counts. 
Experiment 4 – Prior infusion of STO-609 followed by presentation of novel or familiar 
images and by immunohistochemical staining for pCAMKI 
To determine the effect of the CAMKK antagonist STO-609 on the level of 
pCAMKIThre177-stained neurons in the perirhinal region we infused the antagonist prior to 
viewing novel or familiar images in two separate experiments. In both experiments rats with 
implanted guide cannulae directed at the perirhinal cortex (as described in Experiment 1) 
were trained in the paired viewing procedure (as described in Experiment 2) and presented 
with familiar and novel images over 6 days. In each morning session 30 images (FAM set) 
were presented simultaneously to each eye. After a delay of 3h the rats were placed back in 
the apparatus for the afternoon session, in which each eye was shown 15 images from the 
FAM set and 15 novel images. For the novel experiment, on the afternoon of the last day one 
set of 30 novel images (NOV1) was shown to one eye and another set of novel images 
(NOV2) was shown to the other eye. Each animal received an infusion of vehicle to one side 
of the brain and an infusion of STO-609 (as in Experiment 1) to the other side of the brain. 
The use of NOV1 set and NOV2 was counterbalanced with respect to viewing by the left or 
right eye and drug or vehicle infusion side across animals. Infusions of STO-609 (same dose 
as in Experiment 1) were made 15min before viewing of novel images in the afternoon 
session of the last day. Rats were then transcardially perfused 40 min after viewing novel 
images and their brains processed for counting of pCAMKIThre177 stained neurons (as 
described in Experiment 2). For the familiar experiment, on the afternoon of the last day one a 
familiar set of 30 images was shown to each eye. The same infusion time and perfusion times 
were used as in the novel experiment. For verification of cannulae location in this experiment 
see Fig. 1B. 
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Results 
Experiment 1: Object recognition memory following infusion with the CAMKK inhibitor 
STO-609 
To establish the role of CAMKK in the consolidation of recognition memory, the effects of 
local infusion of CAMKK inhibitor STO-609 into the perirhinal cortex were determined on rats’ 
preferential exploration of a novel compared to a familiar object. Memory was tested after a 
20min or a 24h delay. The mean of the time spent exploring the novel object minus that 
exploring the familiar object divided by the total exploration time at test (discrimination ratio: 
DR) was calculated for vehicle or inhibitor infusions. 
The behavioural results established that the CAMKK inhibitor STO-609 impaired 
object recognition memory after a 24h delay when infused 15min before or immediately 
following the acquisition trial; see Fig. 2. No impairment was found when the inhibitor was 
infused 20min after acquisition. Object recognition memory was unaffected over a 20 min 
delay when STO-609 was infused 15min before acquisition. 
In detail, the vehicle controls showed significant preferential exploration of the novel 
rather than the familiar object at both 20min and 24h time intervals (t-tests, p≤0.05) in all tests. 
Additionally, the total time exploring the objects in the acquisition or choice phases showed no 
significant effect of STO-609 compared to vehicle during any of the experiments (see Table 1). 
For the STO-609 condition with a 20min delay, a one factor ANOVA (treatment 
[vehicle/STO-609]) revealed no significant effect of treatment (F(1,8)=5.90, p=0.4). The rats 
receiving STO-609 before acquisition discriminated between novel and familiar objects at the 
20min delay (DR>0: t-test, p=0.05). 
For the STO-609 condition with a 24h delay, two factor ANOVA (treatment, infusion 
time[-15, 0, +20min]) revealed a significant main effect of treatment (F(1,24)= 7.17, p=0.01) and 
a significant interaction of treatment by time (F(2,24)= 4.80, p=0.02). When 2 factor ANOVA 
was applied to the data for infusions 15min before and immediately after acquisition there was 
a significant main effect of treatment (F(1,15)= 9.51, p=0.01) but no significant interaction of 
treatment with time (F(1,15)= 1.36, p=0.3). Rats receiving STO-609 15min before and 0min 
after acquisition did not discriminate novel from familiar (DR>0: t-test, p=0.9, p=0.2). There 
was a significant effect of treatment (STO-609 or vehicle) when the animals received infusion 
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15min before (ANOVA: p=0.03) but not immediately after or 20min after acquisition (ANOVAs: 
p=0.2 for each). Post hoc analyses with Tukey’s test showed significant differences between 
the memory of animals infused with STO-609 at different times: rats infused 15min before 
(p=0.01) and immediately (0min) after the acquisition trial showed significantly (p=0.03) lower 
DR values when compared to those infused 20min after the acquisition trial. 
These findings indicate that CAMKK is necessary for long-term (24h) memory and is 
active during the acquisition trial and/or shortly afterwards. Based on this finding we decided 
to investigate the activation of the enzymes immediately downstream of CAMKK (CAMKI and 
CAMKIV) following the viewing of novel or familiar images. CAMKK activates CAMKI and 
CAMKIV through phosphorylation of their Threonine177 and Threonine196 residues respectively. 
We used immumohistochemistry to label these residues and by doing so obtain a measure of 
CAMKI and CAMKIV activity. Initially pilot experiments were performed to determine the 
cytological distribution of pCAMKIThre177 and pCAMKIVThre196. 
Experiment 2: Immunohistochemical imaging and Western blotting of pCAMKI and 
pCAMKIV antibodies within perirhinal cortex and Te2 
Immunohistochemistry for pCAMKIThre177 revealed staining of neuronal somal 
cytoplasm and apical dendrites. In many cases the stained neurons were identifiably 
pyramidal cells and the staining extended to the apical dendrites of approximately 30% of 
these neurons (Fig. 3). This distribution is consistent with a cytoplasmic occurrence within 
neurons (Picciotto et al., 1995). Further, another commercially available antibody showed a 
similar distribution with staining occurring in the cytoplasm (Abcam, UK: catalog # ab62215). 
Phospho-CAMKIVThre196 staining was principally in pyramidal cells. The staining occurred 
peripherally within the somal cytoplasm and extended to the apical dendrites of approximately 
80% of these pyramidal neurons (Fig. 3). A similar distribution was found with a different 
commercially available antibody for pCAMKIVthr196-200: labelling occurred in apical dendrites 
and cytoplasm (Abcam, UK: catalog # ab59424). This distribution for pCAMKIV differs from 
the occurrence within neuronal nuclei reported by (Jensen et al., 1991). 
Because of this discrepancy with the expected CAMKIV localisation, western blots 
were run to check for the specificity of the antibodies used (Fig. 4). The western blot for the 
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pCAMKIV antibody revealed bands at 60kDa and 70kDa. The 60kDa is in close agreement 
with the CAMKIV molecular weight of 60kDa; however the presence of the weaker band at 
70kDa probably reflects nonspecific binding. The western blot for the pCAMKI antibody 
revealed bands at 42kDa and 84kDa. The 42kDa is in close agreement with the CAMKI 
molecular weight of 45kDa. The presence of the weaker band at 84kDa probably reflects 
dimmers of the CAMKI molecule (Kambe et al., 2010). These results indicated that the 
pCAMKI antibody was more selective than the pCAMKIV antibody. 
Experiment 3: Quantification of pCAMKIThre177 and pCAMKIVThre196 -stained neurons in 
the brain following exposure to novel or familiar images 
We quantified levels of pCAMKI and pCAMKIV expression at different times following 
the viewing or novel or familiar images by counting immunohistochemically labelled neurons 
in the perihinal cortex and in control regions. Using a paired viewing procedure (Zhu et al., 
1996; Warburton et al., 2005), novel and familiar images were presented simultaneously on 
computer monitors positioned in the left and right-hand visual hemifields, so as to restrict 
initial visual processing to the opposite hemisphere of the brain. Immunohistochemical 
staining for the activated forms of pCAMKIThr177 and pCAMKIVThr196 was performed in 
hemispheres primarily processing novel and those primarily processing familiar images 
(‘novel’ and ‘familiar’ hemispheres) from brains perfused at different times following the 
viewing of the images. To compare differences in the relative expression of pCAMKI and 
pCAMKIV, neurons were counted in novel compared to familiar hemispheres. 
PhosphoCAMKIThre177 counts: 
Labelling of pCAMKI labelled neurons was strong in all areas of the brain studied and 
occurred through layers II to VI. Phospho-CAMKI counts were made of approximately oval 
shaped somata with continuous staining through the cytoplasm (Fig. 5). The overall 3 factor 
ANOVA of raw counts (novelty[novel,familiar], area[perirhinal and Te2, control regions 
(auditory, entorhinal cortex, V1 and hippocampus)], time) showed a significant interaction of 
novelty by time (F3,21 =3.62, p=0.03) but no significant interaction of novelty by area (F15,21 <1, 
14 
p=0.8) or novelty by area by time (F1,21 <1 , p=0.1) and no significant main effect of novelty 
(F1,21 =3.26, p=0.09). 
For the designed comparison seeking effects within perirhinal cortex, 2 factor ANOVA 
showed a significant interaction of novelty by time (F3,21 =3.15, p<0.05) and a significant main 
effect of novelty (F1,21 =6.04, p=0.02). Post hoc ANOVA tests revealed that counts in the 
perirhinal cortex for the familiar hemisphere were significantly higher than those for the novel 
hemisphere at 10min (p=0.03) and 40min (p=0.05) but not at 70 (p=0.4) or 100min (p=0.07) 
(Fig. 5). A post hoc Tukey test on the differences between novel and familiar counts revealed 
a significantly greater difference in counts at 40min than at 70min (p=0.02). 
The other regions showed no significant effect of novelty (auditory, lateral entorhinal 
and visual cortices, area Te2 and hippocampus: p=0.9, 0.8, 0.9, 0.3 and 0.2, respectively) 
and no significant interaction of novelty by time (p=0.4, 0.1, >0.9, 0.3 and >0.9). 
PhosphoCAMKIVThre196 counts: 
Labelling of pCAMKIV labelled neurons was strong in some cortical regions such as 
the auditory cortex but was weaker in the perirhinal cortex and area Te2. Staining occurred 
through layers II-VI. Phospho-CAMKIV counts were made of somata (Table 2). Perirhinal 
counts were in the region of 30 per counting frame compared to ~200 for pCAMKI (see also 
Fig. 7). The overall 3 factor ANOVA (novelty [novel,familiar], area[auditory, entorhinal cortex, 
perirhinal cortex, Te2 and V1], time) showed a significant interaction of novelty by time (F3,80 
=3.20, p=0.05) but no significant interaction of novelty by time by area (F12,80 <1 , p=0.7) and 
no significant main effect of novelty (F1,80 <1 , p=0.9). There was no significant effect of novelty 
for any individual area. For the designed comparison seeking effects within perirhinal cortex, 
2 factor ANOVA showed no significant effects (see Table 2 for means and SEMs of the 
counts). 
Staining of pCAMKIV in the hippocampus appeared qualitatively greater than that 
seen in the perirhinal cortex. It formed a continuous band within the pyramidal layer of CA1, 
preventing the counting of individual neurons. Therefore a measurement of average staining 
intensity was made for each counting frame. A two factor ANOVA (novelty [novel,familiar], 
time) for these CA1 measurements of staining showed no significant effect of novelty (F1,20 <1, 
p=0.4) and no significant interaction of novelty by time (F3,20 <1 , p=0.5). 
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Double-labelling of pCAMKI and pCAMKIV 
The immunohistochemical experiments (Experiment 2) showed that both pCAMKI 
and pCAMKIV labelled neurons occurred in the perirhinal cortex. To determine whether 
pCAMKI and pCAMKIV were co-localised within neurons, sections from a rat perfused 10min 
after viewing novel and familiar images, were doubly-labelled for the two activated enzymes 
(Fig. 6). The double-labelling revealed that a small proportion of neurons (~25%) within the 
perirhinal cortex were co-labelled for both pCAMKI and pCAMKIV (Fig. 6C). Fig. 6 also 
illustrates that many more perirhinal neurons were labelled for pCAMKI than for pCAMKIV. 
Experiment 4: Effect of prior infusion of STO-609 on levels of pCAMKI-stained neurons 
in the brain following exposure to novel or familiar images 
The behavioural experiments established that inhibition of CAMKK impaired object 
recognition memory (Experiment 1) and the immunohistochemical experiments established 
that the activation of CAMKI was differentially regulated by viewing novel or familiar images 
(Experiment 3). To determine whether CAMKK inhibition disrupted the differential expression 
of pCAMKI produced by viewing novel or familiar images, counts of pCAMKI-stained neurons 
were made following the infusion of the CAMKK inhibitor STO-609 into the perirhinal cortex. 
Effects of STO-609 on counts of pCAMKIV stained perirhinal neurons were not sought 
because these did not differ significantly following the viewing of novel or familiar images. 
Using the paired viewing procedure, novel images (Novel experiment) or familiar 
images (Familiar experiment) were presented simultaneously to both eyes on computer 
monitors positioned in the left and right visual hemifields. Fifteen minutes before the final 
viewing of the images rats underwent an infusion of vehicle into perirhinal cortex in one 
hemisphere and of STO-609 in the other. Infused at this time, STO-609 impaired object 
recognition memory (Experiment 1 : see Fig.2). Rats were perfused 40min following the final 
viewing of novel/familiar images, the time at which were found different counts of pCAMKI 
stained neurons following viewing of novel compared to familiar images (Experiment 3: see 
Fig. 5). 
Overall analysis of the combined data for the novel and familiar experiments by three 
factor ANOVA (novelty [novel or familiar stimuli], treatment [vehicle/STO-609], area[auditory 
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cortex, entorhinal cortex, perirhinal cortex, Te2, hippocampus, V1]) of raw pCAMKI counts 
revealed no significant main effect of treatment (F1,13 = 1.1, p=0.3), nor interaction of 
treatment by area by novelty (F1,9 = 2.8, p=0.09) but the interaction of treatment by area was 
significant (F1,9 = 4.9, p=0.02); Fig. 7. 
For the designed comparison seeking effects within perirhinal cortex, two factor 
ANOVA showed a significant effect of treatment for perirhinal cortex (p=0.001). For the novel 
pictures, STO-609 infusion significantly reduced pCAMKI counts in the perirhinal cortex by 
23% compared to vehicle (ANOVA; p=0.03). For the familiar pictures, STO-609 infusion 
significantly reduced pCAMKI counts in the perirhinal cortex by 16% compared to vehicle 
(ANOVA; p=0.02). The reduction in counts was not significantly different for the novel and 
familiar pictures (ANOVA; p=0.6). 
Within the neighbouring, non-infused regions, there were significant effects of 
treatment for area Te2 (ANOVA; p=0.03) and lateral entorhinal cortex (ANOVA; p=0.05) but 
no significant differences between the reductions for novel and familiar pictures. The 
reduction reached significance in lateral entorhinal cortex (p=0.02) for the familiar but not the 
novel pictures, and approached significance for the familiar pictures in Te2 (p=0.07); Fig. 7. 
These results show that perirhinal infusion of STO-609 produces a reduction in 
counts of neurons expressing its reaction product, pCAMKI, following both viewing of novel 
and familiar images, in consistency with the role of STO-609 as an inhibitor of CAMKK. These 
reductions are found in perirhinal cortex but also in neighbouring lateral entorhinal cortex and 
area Te2. 
Discussion 
The effect of the CAMKK inhibitor STO-609 on recognition memory 
The results demonstrate that long-term (24h) object recognition memory is impaired 
when the CAMKK inhibitor, STO-609, is infused into perirhinal cortex prior to or immediately 
after acquisition. To our knowledge this is the first study to show STO-609 impairs memory. 
As impairment was found for an infusion immediately after acquisition, the action of STO-609 
is most readily explained as being on consolidation mechanisms rather than on acquisition. 
As no impairment was found for infusions 20 min after acquisition, the effect must be on early 
consolidation. These results therefore indicate a role for CAMKK in the early consolidation of 
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long-term recognition memory. Recognition memory measured after a 20 min delay was 
unimpaired. A long-term but not shorter-term memory impairment has also been found for 
mutant mice with a deleted CAMKKβ gene where the impairment was in memory for social 
transmission of food preferences (Peters et al., 2003). 
Immunohistochemical imaging of pCAMKI and pCAMKIV following viewing of novel or 
familiar images 
In support of a mnemonic role for CAMKK in perirhinal cortex, the processing of 
familiar pictures resulted in an enhanced level of immunoreactivity of the CAMKK reaction 
product, pCAMKIthre177, compared to the processing of novel pictures. The direction of this 
differential change (familiar > novel) is the opposite to that found for Fos (Zhu et al., 1995; 
Zhu et al., 1996; Wan et al., 1999), phosphorylated CREB (Warburton et al., 2005) and 
pCAMKIIα (Tinsley et al., 2009). Moreover, counts of pCAMKI stained neurons were reduced 
following infusion of STO-609 into the perirhinal cortex after the viewing of familiar as well as 
novel pictures. The reductions are consistent with the role of STO-609 in inhibiting CAMKK, 
which in turn phosphorylates the threonine177 residue present on pCAMKI. The 
immunohistochemical results establish a differential role for CAMKK in the processing of 
familiar compared to novel stimuli, but do not exclude a role in processing both novel and 
familiar stimuli. They raise the possibility that CAMKK might be involved in reconsolidation 
mechanisms related to re-exposure to the familiar stimuli in addition to consolidation 
mechanisms for novel stimuli. As the perceptual demands of the object recognition memory 
task were low and behavioural impairment was found when the infusion was after acquisition, 
it is implausible that the impairment was produced by effects upon visual perceptual rather 
than mnemonic processing. The absence of an effect on recognition memory at a 20min 
delay additionally suggests that the major effect of STO-609 was not on perceptual processes. 
Differential pCAMKI activation occurred 10-40min after viewing images, a time course 
consistent with that of the impairment of object recognition memory produced by STO-609 
infusion. STO-609 needed to be active during and immediately after acquisition; infusion 
20min after acquisition (resulting in CAMKK inhibition >~ 30min after acquisition) was 
ineffective. This time course of pCAMKI activation is also consistent with that (up to 60min) 
produced by LTP in hippocampal cell cultures, that activation also being blocked by STO-609 
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(Schmitt et al., 2005). CAMKK and pCAMKI activation begins and ends earlier after 
recognition memory acquisition (~10-40min) than does activation of pCAMKII (~20-100min) 
(Tinsley et al., 2009). 
The STO-609 infusion in perirhinal cortex produced significant reductions in pCAMKI 
activation in the neighbouring regions of area Te2 and lateral entorhinal cortex, the reductions 
being of comparable magnitude to those in perirhinal cortex and not differing significantly for 
novel and familiar images. It is unlikely that these reductions are primarily due to spread of 
the infusate. Data from others (Martin, 1991; Izquierdo et al., 2000; Attwell et al., 2001) and 
our own findings indicate that perirhinal infusions reach most of perirhinal cortex as previously 
defined (Shi and Cassell, 1999); however, the spread into entorhinal cortex and area Te2 is 
limited (<10%). Accordingly, it seems that inhibition of CAMKK in perirhinal cortex reduces 
pCAMK1 activation in area Te2 and lateral entorhinal cortex. Correspondingly, there may be a 
contribution to the impairment of recognition memory produced by the infusion of STO-609 
into perirhinal cortex from such transmitted influences to area Te2 and/or entorhinal cortex. 
Counts of pCAMKIV stained neurons did not differ significantly in response to viewing 
novel compared to familiar images. It is possible that the failure to find a difference was 
because counts for pCAMKIV were lower than for pCAMKI or because of variance introduced 
by the antibody’s non-specific staining. However, in interpreting the effects of CAMKII 
inhibitors, Tinsley et al (2009) argued that pCAMKIV activation is insufficient to support 
recognition memory. The low levels of pCAMKIV staining (even including non-specific staining) 
and lack of differential effect produced by viewing novel and familiar stimuli in the current 
experiments suggest that perirhinal CAMKIV activation is unimportant for object recognition 
memory. The impairment in fear conditioning seen in CAMKIV knockout mice (Wei et al., 
2002) might be due to loss of CAMKIV in regions other than perirhinal cortex, such as the 
hippocampus or amygdala. 
How does CAMKK exert its actions? 
CAMKK activates its substrates via phosphorylation. CAMKK is known to activate the 
MAPKinase pathway as well as CAMKI and CAMKIV (Soderling, 1999). LTP induction in 
hippocampal cell cultures activated CAMKI, Ras-GRF1 (Ras-guanyl-nucleotide releasing 
factor) and ERK (extracellular signal-regulated kinase), the activations all being blocked by 
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STO-609 (Schmitt et al., 2005). At the dose used by Schmitt and colleagues and in the 
present study, STO-609 inhibits CAMKK but does not directly inhibit CAMKI, CAMKIV or 
MAPkinase (Tokumitsu et al., 2002). However, the inhibition of CAMKK (Enslen et al., 1996) 
effects activation not only of CAMKI (Schmitt et al., 2004); and the present findings) but also 
MAPkinase and other kinases (Yano et al., 1998; Soderling, 1999). In particular, CAMKI has 
numerous other substrates such as Synapsin I (Ishida et al., 2003), CREB (Sheng et al., 1991) 
and ATF1 (activating transcription factor) (Sun et al., 1996). Accordingly, inhibition of CAMKK 
may produce effects on recognition memory processes via a number of down-stream 
mechanisms. 
In sum, the results establish that the CAMKK pathway within the perirhinal cortex is 
important for the consolidation of object recognition memory. Immunohistochemical imaging 
for pCAMKI indicated that CAMKI might be involved in reconsolidation mechanisms for 
familiar stimuli in addition to consolidation mechanisms for novel stimuli. The time course of 
activation of pCAMKI after acquisition (~10-40min) is earlier than found (Tinsley et al., 2009) 
for pCAMKII. In contrast to CAMKI and CAMKII, CAMKIV appears to be unimportant for 
perirhinal recognition memory processes. 
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Figure Legends 
Fig 1 . (A) Reconstructed individual infusion sites shown on a representative brain section 
(Paxinos and Watson, 1998) for the 25 animals included in Experiment 1 (filled square 
indicates position of the tip of a guide cannula; note some symbols may overlap). (B) Infusion 
sites from the 15 animals included in Experiment 4 (filled squares indicate the tips of the 
guide cannulae from the novel experiment (n=9), filled squares indicate the tips of the guide 
cannulae from the familiar experiment (n=6)). All cannulae were accurately located in 
perirhinal cortex. C and D, Regions within which pCAMKI and pCAMKIV stained cell counts 
were made, shown on sections -5.2 (C) and -6.3 (D) relative to bregma (Paxinos and Watson, 
1998): auditory cortex (AUD), temporal association cortex (Te2), perirhinal cortex (PRH) 
lateral entorhinal cortex (ENT), primary visual cortex (V1) and the CA1 region of the 
hippocampus (HIPP). 
Fig 2. Effect of perirhinal infusions of the CAMKK inhibitor STO-609 on object recognition 
memory in the rat. Discrimination ratios (DRs) were used as an index of memory performance 
in the preferential object recognition test. Results of infusing (A) vehicle or STO-609 15 min 
before the acquisition trial of the 20 min delay experiment, (B) vehicle or STO-609 at differing 
times relative to acquisition in a 24h delay test. STO-609 infusions 15min before and 0min 
after the acquisition trial produced significantly lower DR values than infusions 20min after the 
acquisition trial (*). # DR >0, p<0.05. 
Fig 3. Immunohistochemical staining for pCAMKIThre177 and pCAMKIVThre196. A-B, 
photomicrographs showing pCAMKI staining in perirhinal cortex (A) and area Te2 (B). 
Phospho-CAMKI staining is seen principally in the somal cytoplasm and apical dendrites. C-D, 
photomicrographs showing pCAMKIV staining in perirhinal cortex (C) and area Te2 (D). 
Phospho-CAMKIV staining is seen principally in the somal cytoplasm and apical dendrites. 
Scale bar = 100μm. 
Fig 4. Western blots of perirhinal cortex (PRH) and area Te2 (TE) for: (A) pCAMKI, revealing 
a strong band at 42kDa (CAMKI molecular weight = 45kDa) and a weaker band at 84kDa 
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probably due to pCAMKI dimmers; and (B) pCAMKIV, revealing a strong band at 
approximately 60kDa (CAMKIV molecular weight = 60kDa) and a weaker band at 
approximately 70kDa due to non-specific binding. 
Fig 5. Graphs of raw counts of pCAMKIThre177 stained neurons in areas: (A) perirhinal 
cortex (PRH), (B) area Te2 (TE), (C) entorhinal cortex (ENT), (D) auditory cortex (AUD), (E) 
visual cortex (V1), and (F) CA1 of the hippocampus (Hipp) at indicated times after viewing 
novel and familiar stimuli. Note significant effect of novelty (*) at 10min (p=0.03) and 40min 
(p=0.05) but not at 70min or 100min within the perirhinal region. 
Fig 6. Double labelling for pCAMKI and pCAMKIV in the perirhinal cortex. Photomicrographs 
of adjacent sections stained for: (A) pCAMKI visualised with DAB, (B) pCAMKIV visualised 
with DAB, and (C) double stained for pCAMKI visualised with DAB (brown) and pCAMKI 
visualised with Vector VIP (purple). In (C) note neurons stained for pCAMKI (black arrow), 
pCAMKIV (green arrow) or pCAMKI and pCAMKIV (blue arrow). Photomicrographs were 
taken at the same magnification. Scale bar = 100μm. 
Fig 7. Effect of infusion of the inhibitor STO-609 on counts of pCAMKIThre177 stained neurons 
following viewing of novel (A) or familiar (B) images. Normalised counts of pCAMKI stained 
neurons 40 min after viewing novel images and following an infusion of STO-609 (filled 
squares) or vehicle (open circles)into perirhinal cortex 15min before viewing of images. Note 
significantly reducd counts in perirhinal and entorhinal cortices following STO-609 infusion (*) 
Abbreviations as for Fig. 5. 
Table 1. Exploration of animals (in seconds) in the acquisition and choice trials. Values shown 
are the mean time exploring both objects in seconds (S.E.M) for vehicle or drug at each of the 
time-points investigated. For acquisition or choice trials groups receiving STO-609 did not 
display significantly different exploration times from their control groups, (ANOVAs, p≤0.05). 
For the 24 h experiments 2 -factor ANOVA(treatment, time) showed no significant effect of 
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treatment on exploration times for acquisition (F1,24 = <1 , p=0.9) or choice trials (F1,24 = <1 , 
p=0.6). 
Table 2. Counts of pCAMKIVThre196 stained neurons within brain regions (auditory, entorhinal, 
perirhinal, TE and V1 cortices) at 10, 40, 70 and 100min after viewing novel or familiar images. 
The values given for hippocampus (CA1) region were provided by an analysis of the average 
staining intensity on counting frames. Statistics for raw counts: a repeated-measures 3 factor 
ANOVA (area, novelty, time) showed a significant interaction of novelty by time (F3,80 =3.20, 
p=0.05). Two factor ANOVA (novelty, area) at 70min showed a significant effect of novelty 
(p=0.05) however this effect was not significant within individual regions. Statistics for 
hippocampal staining: a two factor ANOVA (Novelty, time) showed no significant effect of 
novelty or interaction of novelty by time. Values shown are mean (S.E.M). 
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A B 
Fig 1 . (A) Reconstructed individual infusion sites shown on a representative brain section 
(Paxinos and Watson, 1998) for the 25 animals included in Experiment 1 (filled square 
indicates position of the tip of a guide cannula; note some symbols may overlap). (B) 
Infusion sites from the 15 animals included in Experiment 4 (filled squares indicate the tips 
of the guide cannulae from the novel experiment (n=9), filled squares indicate the tips of 
the guide cannulae from the familiar experiment (n=6)). All cannulae were accurately 
located in perirhinal cortex. C and D, Regions within which pCAMKI and pCAMKIV stained 
cell counts were made, shown on sections -5.2 (C) and -6.3 (D) relative to bregma 
(Paxinos and Watson, 1998): auditory cortex (AUD), temporal association cortex (Te2), 
perirhinal cortex (PRH) lateral entorhinal cortex (ENT), primary visual cortex (V1) and the 
CA1 region of the hippocampus (HIPP). 
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Fig 2. Effect of perirhinal infusions of the CAMKK inhibitor STO-609 on object recognition 
memory in the rat. Discrimination ratios (DRs) were used as an index of memory 
performance in the preferential object recognition test. Results of infusing (A) vehicle or 
STO-609 15 min before the acquisition trial of the 20 min delay experiment, (B) vehicle or 
STO-609 at differing times relative to acquisition in a 24h delay test. STO-609 infusions 
15min before and 0min after the acquisition trial produced significantly lower DR values 
than infusions 20min after the acquisition trial (*). # DR >0, p<0.05. 
0.5 
0.4 
0.3 
0.2 
0.1 
0 
# 
0.4 0.4 0.4 
# 
0.3 0.3 0.3 
0.2 0.2 0.2 
0.1 0.1 0.1 
0 0 0 
28 
PRH TE 
• A 
C 
B 
D 
Fig 3. Immunohistochemical staining for pCAMKIThre177 and pCAMKIVThre196. A-B, 
photomicrographs showing pCAMKI staining in perirhinal cortex (A) and area Te2 (B). 
Phospho-CAMKI staining is seen principally in the somal cytoplasm and apical dendrites. C-
D, photomicrographs showing pCAMKIV staining in perirhinal cortex (C) and area Te2 (D). 
Phospho-CAMKIV staining is seen principally in the somal cytoplasm and apical dendrites. 
Scale bar = 100μm. 
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Fig 4. Western blots of perirhinal cortex (PRH) and area Te2 (TE) for: (A) pCAMKI, 
revealing a strong band at 42kDa (CAMKI molecular weight = 45kDa) and a weaker 
band at 84kDa probably due to pCAMKI dimmers; and (B) pCAMKIV, revealing a 
strong band at approximately 60kDa (CAMKIV molecular weight = 60kDa) and a 
weaker band at approximately 70kDa due to non-specific binding. 
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Fig 5. Graphs of raw counts of pCAMKIThre177 stained neurons in areas: (A) perirhinal 
cortex (PRH), (B) area Te2 (Te2), (C) entorhinal cortex (ENT), (D) auditory cortex (AUD), 
(E) visual cortex (V1), and (F) CA1 of the hippocampus (Hipp) at indicated times after 
viewing novel and familiar stimuli. Note significant effect of novelty (*) at 10min (p=0.03) 
and 40min (p=0.05) but not at 70min or 100min within the perirhinal region. 
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Fig 6. Double labelling for pCAMKI and pCAMKIV in the perirhinal cortex. 
Photomicrographs of adjacent sections stained for: (A) pCAMKI visualised with DAB, (B) 
pCAMKIV visualised with DAB, and (C) double stained for pCAMKI visualised with DAB 
(brown) and pCAMKI visualised with Vector VIP (purple). In (C) note neurons stained for 
pCAMKI (black arrow), pCAMKIV (green arrow) or pCAMKI and pCAMKIV (blue arrow). 
Photomicrographs were taken at the same magnification. Scale bar = 100μm. 
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Fig 7. Effect of infusion of the inhibitor STO-609 on counts of pCAMKIThre177 stained 
neurons following viewing of novel (A) or familiar (B) images. Counts of pCAMKI stained 
neurons 40 min after viewing novel images and following an infusion of STO-609 (filled 
squares) or vehicle (open circles)into perirhinal cortex 15min before viewing of images. 
Note significantly reducd counts in perirhinal and entorhinal cortices following STO-609 
infusion (*) Abbreviations as for Fig. 5. 
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delay 
20min 
24h 
infusate 
vehicle 
STO-609 
Vehicle 
STO-609 
vehicle 
STO-609 
Vehicle 
STO-609 
trial 
acquisition 
acquisition 
choice 
choice 
acquisition 
acquisition 
choice 
choice 
Infusion time relative to the end of the acquisition trial 
-19 0 20 
29.3(2.4) 
30.7(1.9) 
27.6(4.0) 
28.8(4.8) 
36.8(1.4) 33.9(2.9) 28.2(2.1) 
29.7(3.9) 35.7(1.8) 30.9(1.4) 
22.6(3.2) 23.3(2.6) 15.9(1.7) 
22.7(3.7) 23.0(2.1) 21.9(2.6) 
Table 1. Exploration of animals (in seconds) in the acquisition and choice trials. Values shown are the mean 
time exploring both objects in seconds (S.E.M) for vehicle or drug at each of the time-points investigated. For 
acquisition or choice trials groups receiving STO-609 did not display significantly different exploration times 
from their control groups, (ANOVAs, p≤0.05). For the 24 h experiments 2 -factor ANOVA(treatment, time) 
showed no significant effect of treatment on exploration times for acquisition (F1 24 = <1, p=0.9) or choice trials 
(F124 = <1, p=0.6). 
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Perfusion 
time 
10min 
40mim 
70min 
100min 
Image 
type 
Novel 
Familiar 
Novel 
Familiar 
Novel 
Familiar 
Novel 
Familiar 
Auditory 
64.8 (25.7) 
64.8 (29.9) 
17.3 (11.3) 
26.5 (15.7) 
74.3 (47.8) 
56.3 (19.0) 
16.1 (14.3) 
55.6 (20.6) 
Entorhinal 
33.0 (12.3) 
41.7 (13.9) 
7.7 (6.3) 
22.5 (18.0) 
48.3 (17.1) 
27.0 (15.9) 
37.0 (8.5) 
54.7 (16.5) 
Perirhinal 
44.0 (12.4) 
43.6 (16.8) 
8.8 (4.1) 
16.5 (11.9) 
45.1 (15.9) 
33.3 (9.9) 
31.6 (7. 0) 
31.5 (7.4) 
TE 
43.7 (14.2) 
51.0 (19.7) 
10.3 (5.5) 
15.5 (10.3) 
50.5 (16.5) 
42.7 (13.7) 
42.6 (13.9) 
37.6 (10.5) 
V1 
31.6 (8.7) 
58.1 (18.0) 
20.1 (10.6) 
18.8 (10.4) 
68.8 (22.6) 
48.1 (18.2) 
53.8 (24.3) 
37.8 (18.3) 
Hipp (CA1) 
103.6 (5.2) 
104.7 (23.1) 
107.5 (7.3) 
109.5 (4.5) 
116.8 (8.2) 
112.8 (7.8) 
104.8 (3.4) 
96.8 (4.7) 
Table 2. Counts of pCAMKIVThre196 stained neurons within brain regions (auditory, entorhinal, perirhinal, 
TE and V1 cortices) at 10, 40, 70 and 100min after viewing novel or familiar images. The values given for 
hippocampus (CA1) region were provided by an analysis of the average staining intensity on counting 
frames. Statistics for raw counts: a repeated-measures 3 factor ANOVA (area, novelty, time) showed a 
significant interaction of novelty by time (F3,80 =3.20, p=0.05). Two factor ANOVA (novelty, area) at 70min 
showed a significant effect of novelty (p=0.05) however this effect was not significant within individual 
regions. Statistics for hippocampal staining: a two factor ANOVA (Novelty, time) showed no significant 
effect of novelty or interaction of novelty by time. Values shown are mean (S.E.M). 
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